文献速递肝胆胰外科围术期管理与 ERAS

机器人辅助与腹腔镜胰十二指肠切除术的肿瘤学结局比较

Robotic-assisted versus laparoscopic pancreaticoduodenectomy: oncological outcomes.
PubMed 文献 · Surg Endosc · 2017-12-26

该回顾性研究利用美国国家癌症数据库2010–2013年数据,比较机器人辅助(RPD)与腹腔镜(LPD)胰十二指肠切除术的围术期、病理及中期肿瘤学结局。共纳入1623例微创胰十二指肠切除术(MIPD),其中LPD占90%、RPD占10%。两组在淋巴结检出数、切缘状态、住院时间、90天死亡率、30天再入院率及胰腺腺癌中位总生存期上均无差异。

要点

  • RPD与LPD在围术期、病理及中期肿瘤学结局上等效。
  • 胰腺腺癌中位总生存期LPD 20.7个月 vs RPD 22.7个月(P=0.445)。
  • 两组淋巴结检出数、切缘状态、90天死亡率及30天再入院率无差异。

核心结论

  • 在该全国性队列中,LPD与RPD的围术期、病理及中期肿瘤学结局等效。

研究设计与样本

  • 回顾性研究,使用美国国家癌症数据库2010–2013年数据,共纳入1623例微创胰十二指肠切除术(MIPD)病例,其中LPD占90%、RPD占10%。

主要发现

  • RPD更常见于学术中心(89.1% vs LPD 68.1%,P < 0.001)及更高体量中心(RPD中位MIPD/年4.7 vs LPD 3.6,P < 0.001)。
  • 两组在患者及肿瘤相关因素上无差异,治疗肿瘤以腺癌为主(RPD 90.1%,LPD 89.1%)。
  • 两组在检出淋巴结中位数、切缘状态、中位住院时间、90天死亡率或30天再入院率上无差异。
  • 胰腺腺癌中位总生存期LPD 20.7个月 vs RPD 22.7个月(log-rank P = 0.445)。
  • 1年和3年总生存率:LPD为74%和31%,RPD为71%和33%。

临床怎么用

  • 在具备相应技术条件的中心,RPD与LPD均可作为MIPD的可选平台,肿瘤学结局未见差异。

局限性

  • 本研究为回顾性数据库分析,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimally invasive pancreaticoduodenectomy (MIPD) is being performed with increasing frequency for pancreatic cancer, but the most oncologically efficacious surgical platform, whether robotic or laparoscopic, is yet to be determined. Currently, there are no national studies comparing the oncological outcomes between robotic (RPD) and laparoscopic (LPD) pancreaticoduodenectomy. METHODS: This was a retrospective study using the National Cancer Database between 2010 and 2013. We compared the perioperative, pathological, and mid-term oncological outcomes between RPD and LPD. RESULTS: There were 1623 MIPD cases, of which 90% were LPD and 10% were RPD. Most LPD (63%) and RPD (51%) cases were performed at institutions with a volume of ≤ 5 MIPDs per year. There were no differences in patient- and tumor-related factors between the groups. The majority of treated tumors were adenocarcinoma (90.1% for RPD and 89.1% for LPD). RPDs were more likely to be performed at academic centers (89.1%) compared to LPDs (68.1%, P < 0.001) and at higher-volume centers (median MIPD/year of 4.7 for RPD vs 3.6 for LPD, P < 0.001). There was no difference in the median number of examined lymph nodes, margin status, median length of stay, 90-day mortality, or 30-day readmission between groups. There was no difference in median overall survival for pancreatic adenocarcinoma between LPD (20.7 months) and RPD (22.7 months; log-rank P = 0.445). The 1- and 3-year overall survival rates were 74 and 31% for LPD and 71 and 33% for RPD. CONCLUSION: In this national cohort of patients, LPD and RPD were associated with equivalent perioperative, pathological, and mid-term oncological outcomes.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Nassour I, Choti MA, Porembka MR, et al. Robotic-assisted versus laparoscopic pancreaticoduodenectomy: oncological outcomes. Surg Endosc. 2017. PMID: 29280014. doi:10.1007/s00464-017-6002-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。